Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480306 | 1.00 | KDM4E (0.41) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL234027 | 0.74 | KDM4E (0.55) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL28283233 | 0.74 | KDM4E (0.55) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL21950883 | 0.73 | KDM4E (0.43) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL317949 | 0.73 | MAPT (0.50) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL2620018 | 0.73 | MAPT (0.50) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL20450103 | 0.73 | OAT (0.33) | — | |
| SCHEMBL5658455 | 0.71 | ALDH1A1 (0.41) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL7566870 | 0.70 | MAPT (0.47) | KDM4EMAPTKMT2AALOX15MEN1 | |
| SCHEMBL7567655 | 0.70 | MAPT (0.47) | KDM4EMAPTKMT2AALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022178-B1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE HEALTHCARE LTD (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-2552891-B1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LTD (GB) | 2018-08-08 | — | — | EP | disclosed |
| US-9815785-B2 | Enantiomeric separation and purification of 2,3,4,9-tetrahydro-1H-carbazole-4-carboxylic acid amide derivatives | GE HEALTHCARE LIMITED (GB) | 2017-11-14 | — | — | US | disclosed |
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-20160168091-A1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| EP-3022178-A1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE Healthcare Limited (GB) | 2016-05-25 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| WO-2015040087-A1 | MACROPHAGE IMAGING | GE HEALTHCARE LIMITED (GB) | 2015-03-26 | — | — | WO | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | KDM4E 146/4885MAPT 2852/4885KMT2A 326/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | KDM4E 1277/4885MAPT 4632/4885KMT2A 1543/4885 |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GABRA5, GABRP, GABRA4 | KDM4E 1395/4885MAPT 2686/4885KMT2A 1560/4885 |
| US-20160168091-A1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | IDO2, IDO1, TPH2 | KDM4E 1531/4885MAPT 3310/4885KMT2A 1202/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | KDM4E 782/4885MAPT 1078/4885KMT2A 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.